Companies: 10,795·Total market cap: $144.5T
Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

CYCCNASDAQHealthcare
$6.37
$-0.41(-5.98%)
Market Cap$10608329
P/E Ratio
52W High$597.59973
52W Low$3.0801

Cyclacel Pharmaceuticals, Inc.(CYCC)· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。

FMP · CYCC · 截至 2026-06-09

财务报表

Revenue · Gross Profit · Net Income
Breakdown2025-122024-122023-122022-122021-12
Revenue
Revenue$0.75M$0.04M$0.42M$0.00M$0.00M
Cost of Revenue$0.61M$0.00M$0.00M$0.03M$0.04M
Gross Profit$0.14M$0.04M$0.42M($0.03M)($0.04M)
Gross Margin %(computed)18.47%100.00%100.00%
Operating Expenses
R&D Expenses$0.85M$6.66M$19.16M$20.27M$14.93M
G&A Expenses$7.72M$5.39M$6.72M$7.38M$7.46M
Total Operating Expenses$8.56M$12.05M$25.87M$27.66M$22.39M
Operating Income($8.43M)($12.00M)($25.45M)($27.66M)($22.94M)
Operating Margin %(computed)
Interest Income$0.06M$0.01M$0.27M$0.21M$0.02M
Interest Expense$0.00M$0.00M$0.00M$0.00M$0.00M
Income Before Tax($3.00M)($11.99M)($25.55M)($25.91M)($22.18M)
Income Tax Expense($0.01M)($0.78M)($3.00M)($4.72M)($3.85M)
Net Income($3.00M)($11.21M)($22.55M)($21.20M)($18.89M)
Net Margin %(computed)-401.34%
Per Share & EBITDA
EPS (Basic)$-6.45$-1.36$-28.67$-28.50$-32.10
Wtd Avg Shares2.19M8.31M0.80M0.75M0.60M
EBITDA($8.43M)($12.00M)($25.42M)($27.62M)($22.69M)
EBITDA Margin %(computed)

数据来源:Financial Modeling Prep · 最后更新:2026-06-09 · USD · M

深入了解Cyclacel Pharmaceuticals, Inc.

关于Cyclacel Pharmaceuticals, Inc.(CYCC)损益表

Cyclacel Pharmaceuticals, Inc.(CYCC)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,CYCC实现营收$0.00B,毛利润$0.00B(毛利率18.47%),净利润($0.00B)(净利率-401.34%)。

常见问题

CYCC · 4 问

Cyclacel Pharmaceuticals, Inc.(CYCC)2025财年营收为$0.00B,同比up1637.2%。

CYCC revenueCYCC salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09